CIT-013 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2025
How each study uses CIT-013 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Citryll BV (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CIT-013.
- Apr 2027A Study With CIT-013 in HS PatientsPhase 2 · Citryll BV
Studies
Open first, then newest update. How each study uses CIT-013 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013CompletedPhase 1Citryll BVNCT07499908Written as CIT-013 high dose
- A Study With CIT-013 in HS PatientsActive, not recruitingPhase 2Citryll BVNCT06993233Written as CIT-013 high dose
- A Study With CIT-013 in RA PatientsCompletedPhase 2Citryll BVNCT06567470Written as CIT-013 low dose